Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

ACRVAcrivon Therapeutics, Inc.

Nasdaq · CIK 0001781174
Filer category<br>Emerging growth company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1231
XBRL facts199

Identity from submissions API

NameAcrivon Therapeutics, Inc.
CIK0001781174
TickersACRV
ExchangesNasdaq
Entity typeoperating
Category<br>Emerging growth company
SIC2834 Pharmaceutical Preparations
EIN825125532
LEI—
Fiscal year end1231
State of incorporation—
Phone617-207-8979
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • None listed.
Business address
480 ARSENAL WAY, SUITE 100
WATERTOWN
MA
02472
MA
Mailing address
480 ARSENAL WAY, SUITE 100
WATERTOWN
MA
02472
MA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

359 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-20 8-K 8-K 7.01,9.01 0001193125-26-470245 001-41551 261579243 34 7669624 1 1
2026-11-19 4 FORM 4 0000905148-26-005056 5146
2026-11-19 4 FORM 4 0000905148-26-005055 5159
2026-11-19 4 FORM 4 0000905148-26-005053 5169
2026-11-19 4 FORM 4 0000905148-26-005051 5205
2026-11-19 4 FORM 4 0000905148-26-005050 9006
2026-11-17 144 xsl144X01/primary_doc.xml 0000905148-26-005014 001-41551 261567662 33 7467
2026-11-17 144 xsl144X01/primary_doc.xml 0000905148-26-005013 001-41551 261567659 33 7493
2026-11-16 S-3 S-3 0001193125-26-463828 333-300095 261562762 33 850727 1 1
2026-11-16 8-K 8-K 2.02,9.01 0001193125-26-463444 001-41551 261560474 34 464668 1 1
2026-11-16 10-Q 10-Q 0001193125-26-463419 001-41551 261560349 34 8334819 1 1
2026-11-10 8-K 8-K 7.01,9.01 0001193125-26-455669 001-41551 261541307 34 13901065 1 1
2026-11-06 8-K 8-K 8.01,9.01 0001193125-26-450779 001-41551 261529411 34 278182 1 1
2026-10-26 4 FORM 4 0000905148-26-004554 4993
2026-10-07 4 FORM 4 0000905148-26-004399 5155
2026-09-02 4 FORM 4 0000905148-26-004065 7248
2026-09-02 3 FORM 3 0000905148-26-004064 14671
2026-08-27 4 FORM 4 0000905148-26-003968 8236
2026-08-25 144 xsl144X01/primary_doc.xml 0000905148-26-003924 001-41551 261317355 33 6796
2026-08-20 4 FORM 4 0000905148-26-003840 4699
2026-08-20 4 FORM 4 0000905148-26-003839 4712
2026-08-20 4 FORM 4 0000905148-26-003838 4722
2026-08-20 4 FORM 4 0000905148-26-003837 4717
2026-08-20 4 FORM 4 0000905148-26-003836 8515
2026-08-13 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001875620-26-000015 005-93824 261271274 34 17355
2026-08-12 S-8 S-8 0001193125-26-347003 333-298271 261268190 33 189039 1 1
2026-08-12 8-K 8-K 2.02,9.01 0001193125-26-346859 001-41551 261267566 34 435755 1 1
2026-08-12 10-Q 10-Q 0001193125-26-346819 001-41551 261267452 34 8074818 1 1
2026-08-06 4 FORM 4 0000905148-26-003499 4669
2026-07-23 4 FORM 4 0000905148-26-003334 4712
2026-06-22 4 xslF345X06/form4-06222026_080632.xml 0001231919-26-000686 14153
2026-06-22 4 FORM 4 0000905148-26-003042 5330
2026-06-22 4 FORM 4 0000905148-26-003041 5411
2026-06-22 4 FORM 4 0000905148-26-003035 5373
2026-06-22 4 FORM 4 0000905148-26-003034 5574
2026-06-22 4 FORM 4 0000905148-26-003033 6038
2026-06-22 4 FORM 4 0000905148-26-003024 5422
2026-06-17 8-K 8-K 5.02,5.07,9.01 0001193125-26-274410 001-41551 261099550 34 583104 1 1
2026-05-26 4 FORM 4 0000905148-26-002652 7685
2026-05-22 DEFA14A DEFA14A 0001193125-26-236858 001-41551 261013634 34 4858294 1 1
2026-05-20 4 xslF345X06/form4-05202026_080548.xml 0001231919-26-000517 15298
2026-05-20 4 FORM 4 0000905148-26-002563 4777
2026-05-20 4 FORM 4 0000905148-26-002562 4858
2026-05-20 4 FORM 4 0000905148-26-002560 4820
2026-05-20 4 FORM 4 0000905148-26-002559 5021
2026-05-20 4 FORM 4 0000905148-26-002558 5451
2026-05-20 4 FORM 4 0000905148-26-002557 4822
2026-05-20 4 FORM 4 0000905148-26-002556 4995
2026-05-20 4 FORM 4 0000905148-26-002555 5028
2026-05-20 4 FORM 4 0000905148-26-002553 5008
2026-05-20 4 FORM 4 0000905148-26-002552 4982
2026-05-20 4 FORM 4 0000905148-26-002551 5018
2026-05-20 4 FORM 4 0000905148-26-002550 5013
2026-05-20 4 FORM 4 0000905148-26-002549 8810
2026-05-18 4 FORM 4 0000905148-26-002502 4700
2026-05-18 4 FORM 4 0000905148-26-002501 4715
2026-05-18 4 FORM 4 0000905148-26-002500 4725
2026-05-18 4 FORM 4 0000905148-26-002499 4719
2026-05-18 4 FORM 4 0000905148-26-002498 8517
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001104659-26-062728 005-93824 26989135 34 17994
2026-05-13 10-Q 10-Q 0001193125-26-221634 001-41551 26973386 34 7200371 1 1
2026-05-13 8-K 8-K 2.02,9.01 0001193125-26-221626 001-41551 26973338 34 389544 1 1
2026-04-30 ARS ARS 0001193125-26-194214 001-41551 26920318 34 1830119
2026-04-30 DEFA14A DEFA14A 0001193125-26-194211 001-41551 26920311 34 3501317 1 1
2026-04-30 DEF 14A DEF 14A 0001193125-26-194206 001-41551 26920294 34 5325472 1 1
2026-04-23 SCHEDULE 13D/A xslSCHEDULE_13D_X02/primary_doc.xml 0001346824-26-000116 005-93824 26889064 34 15783
2026-04-23 4 xslF345X06/form4-04232026_080403.xml 0001231919-26-000396 13625
2026-04-21 4 FORM 4 0000905148-26-001768 4715
2026-03-23 SCHEDULE 13D/A xslSCHEDULE_13D_X02/primary_doc.xml 0001346824-26-000081 005-93824 26782604 34 15443
2026-03-19 S-8 S-8 0001193125-26-115150 333-294425 26772425 33 190951 1 1
2026-03-19 8-K 8-K 2.02,7.01,9.01 0001193125-26-115139 001-41551 26772402 34 26005148 1 1
2026-03-19 10-K 10-K 0001193125-26-115123 001-41551 26772384 34 12398081 1 1
2026-03-03 4 FORM 4 0000905148-26-001121 5334
2026-03-03 4 FORM 4 0000905148-26-001120 5370
2026-03-03 4 FORM 4 0000905148-26-001119 5397
2026-03-03 4 FORM 4 0000905148-26-001118 5306
2026-03-03 4 FORM 4 0000905148-26-001117 5357
2026-03-03 4 FORM 4 0000905148-26-001116 5354
2026-03-03 4 FORM 4 0000905148-26-001115 9689
2026-03-02 8-K 8-K 1.02 0001193125-26-085516 001-41551 26708237 34 142207 1 1
2026-02-27 8-K 8-K 7.01,9.01 0001193125-26-079500 001-41551 26693005 34 2002127 1 1
2026-02-24 4 FORM 4 0000905148-26-001010 7475
2026-02-18 4 FORM 4 0000905148-26-000939 4564
2026-02-18 4 FORM 4 0000905148-26-000937 4578
2026-02-18 4 FORM 4 0000905148-26-000936 4588
2026-02-18 4 FORM 4 0000905148-26-000935 4582
2026-02-18 4 FORM 4 0000905148-26-000934 8309
2026-01-21 4 xslF345X05/form4.xml 0000905148-26-000281 4417
2026-01-16 4 xslF345X05/form4.xml 0000905148-26-000226 7628
2026-01-16 4 xslF345X05/form4.xml 0000905148-26-000225 4743
2026-01-15 4 xslF345X05/form4.xml 0000905148-26-000212 4792
2026-01-08 8-K 8-K 7.01,9.01 0001193125-26-007077 001-41551 26517609 34 17491516 1 1
2026-01-08 8-K 8-K 2.02,7.01,8.01,9.01 0001193125-26-007007 001-41551 26517396 34 331988 1 1
2025-11-25 4 xslF345X05/form4.xml 0000905148-25-004179 7264
2025-11-21 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-115063 005-93824 251509140 34 29242
2025-11-18 4 xslF345X05/form4.xml 0000905148-25-004131 4403
2025-11-18 4 xslF345X05/form4.xml 0000905148-25-004130 4418
2025-11-18 4 xslF345X05/form4.xml 0000905148-25-004129 4428
2025-11-18 4 xslF345X05/form4.xml 0000905148-25-004128 4422
2025-11-18 4 xslF345X05/form4.xml 0000905148-25-004127 8096
2025-11-14 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-112501 005-93824 251485964 34 18214
2025-11-13 10-Q 10-Q 0001193125-25-280215 001-41551 251478762 34 8292576 1 1
2025-11-13 8-K 8-K 2.02,9.01 0001193125-25-280172 001-41551 251478533 34 436069 1 1
2025-10-21 4 xslF345X05/form4.xml 0000905148-25-003637 4418
2025-10-03 4 xslF345X05/form4.xml 0000905148-25-003507 5213
2025-10-03 4 xslF345X05/form4.xml 0000905148-25-003506 4418
2025-09-05 8-K 8-K 7.01,9.01 0001193125-25-197250 001-41551 251297055 34 33782534 1 1
2025-08-25 4 xslF345X05/form4.xml 0000905148-25-003121 7275
2025-08-18 4 xslF345X05/form4.xml 0000905148-25-003043 16314
2025-08-18 4 xslF345X05/form4.xml 0000905148-25-003042 4418
2025-08-18 4 xslF345X05/form4.xml 0000905148-25-003041 16356
2025-08-18 4 xslF345X05/form4.xml 0000905148-25-003040 16332
2025-08-18 4 xslF345X05/form4.xml 0000905148-25-003039 8096
2025-08-13 10-Q 10-Q 0000950170-25-108054 001-41551 251211890 34 8612063 1 1
2025-08-13 8-K 8-K 2.02,9.01 0001193125-25-179834 001-41551 251211828 34 436336 1 1
2025-08-13 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001875620-25-000020 005-93824 251209628 34 17238
2025-08-05 4 xslF345X05/form4.xml 0000905148-25-002732 4375
2025-07-21 4 xslF345X05/form4.xml 0000905148-25-002493 4412
2025-06-17 4 xslF345X05/form4-06182025_120627.xml 0001415889-25-017627 13821
2025-06-17 4 xslF345X05/form4.xml 0000905148-25-002177 17583
2025-06-17 4 xslF345X05/form4.xml 0000905148-25-002174 16897
2025-06-17 4 xslF345X05/form4.xml 0000905148-25-002173 17031
2025-06-17 4 xslF345X05/form4.xml 0000905148-25-002172 16774
2025-06-17 4 xslF345X05/form4.xml 0000905148-25-002171 17151
2025-06-17 4 xslF345X05/form4.xml 0000905148-25-002170 16769
2025-06-13 8-K 8-K 5.07 0000950170-25-086246 001-41551 251047016 34 174381 1 1
2025-06-04 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000950170-25-081605 005-93824 251023093 34 10284
2025-05-23 4 xslF345X05/form4.xml 0000905148-25-001900 31367
2025-05-16 4 xslF345X05/form4.xml 0000905148-25-001824 4401
2025-05-16 4 xslF345X05/form4.xml 0000905148-25-001823 4410
2025-05-16 4 xslF345X05/form4.xml 0000905148-25-001822 4426
2025-05-16 4 xslF345X05/form4.xml 0000905148-25-001821 4402
2025-05-16 4 xslF345X05/form4.xml 0000905148-25-001820 8092
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001104659-25-049618 005-93824 25955926 34 18413
2025-05-14 S-8 S-8 0001193125-25-119914 333-287277 25946645 33 79173
2025-05-14 10-Q 10-Q 0000950170-25-071427 001-41551 25945769 34 8321281 1 1
2025-05-14 8-K 8-K 2.02,9.01 0000950170-25-071385 001-41551 25945536 34 397003 1 1
2025-05-01 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0000950170-25-062201 005-93824 25905142 34 10557
2025-05-01 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-25-008341 11166
2025-04-29 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-25-008214 13090
2025-04-25 ARS ARS 0000950170-25-058357 001-41551 25870128 34 21259900
2025-04-25 DEFA14A DEFA14A 0000950170-25-058356 001-41551 25870123 34 3724363 1 1
2025-04-25 DEF 14A DEF 14A 0000950170-25-058352 001-41551 25870114 34 5381248 1 1
2025-04-21 3 xslF345X02/form3.xml 0000905148-25-001264 15281
2025-04-18 4 xslF345X05/form4.xml 0000905148-25-001257 4411
2025-04-07 8-K 8-K 7.01,9.01 0000950170-25-051576 001-41551 25818132 34 272003 1 1
2025-04-03 4 xslF345X05/form4.xml 0000905148-25-001076 16939
2025-04-03 4 xslF345X05/form4.xml 0000905148-25-001075 5142
2025-04-03 3 xslF345X02/form3.xml 0000905148-25-001074 19719
2025-03-28 S-8 S-8 0001193125-25-066369 333-286208 25781776 33 73388
2025-03-27 8-K 8-K 7.01,9.01 0000950170-25-046163 001-41551 25780127 34 443253 1 1
2025-03-27 10-K 10-K 0000950170-25-046056 001-41551 25779305 34 100633020 1 1
2025-03-25 8-K 8-K 2.02,7.01,8.01,9.01 0000950170-25-044549 001-41551 25769295 34 25633484 1 1
2025-03-14 8-K 8-K 5.02,9.01 0000950170-25-039520 001-41551 25740904 34 253205 1 1
2025-03-04 4 xslF345X05/form4.xml 0000905148-25-000842 5189
2025-03-04 4 xslF345X05/form4.xml 0000905148-25-000840 5196
2025-03-04 4 xslF345X05/form4.xml 0000905148-25-000838 5211
2025-03-04 4 xslF345X05/form4.xml 0000905148-25-000836 5212
2025-03-04 4 xslF345X05/form4.xml 0000905148-25-000834 5209
2025-03-04 4 xslF345X05/form4.xml 0000905148-25-000831 5218
2025-03-04 4 xslF345X05/form4.xml 0000905148-25-000828 9498
2025-02-25 4 xslF345X05/form4.xml 0000905148-25-000764 7288
2025-02-19 4 xslF345X05/form4.xml 0000905148-25-000730 4419
2025-02-19 4 xslF345X05/form4.xml 0000905148-25-000729 4427
2025-02-19 4 xslF345X05/form4.xml 0000905148-25-000728 4439
2025-02-19 4 xslF345X05/form4.xml 0000905148-25-000727 4443
2025-02-19 4 xslF345X05/form4.xml 0000905148-25-000726 4437
2025-02-19 4 xslF345X05/form4.xml 0000905148-25-000725 8119
2025-01-22 4 xslF345X05/form4.xml 0000905148-25-000168 4427
2024-11-27 4 xslF345X05/form4.xml 0000905148-24-003295 5196
2024-11-27 4 xslF345X05/form4.xml 0000905148-24-003293 5208
2024-11-27 4 xslF345X05/form4.xml 0000905148-24-003291 5212
2024-11-27 4 xslF345X05/form4.xml 0000905148-24-003289 5206
2024-11-27 4 xslF345X05/form4.xml 0000905148-24-003287 9495
2024-11-25 4 xslF345X05/form4.xml 0000905148-24-003270 7290
2024-11-18 4 xslF345X05/form4.xml 0000905148-24-003228 4419
2024-11-18 4 xslF345X05/form4.xml 0000905148-24-003227 4428
2024-11-18 4 xslF345X05/form4.xml 0000905148-24-003226 4440
2024-11-18 4 xslF345X05/form4.xml 0000905148-24-003225 4444
2024-11-18 4 xslF345X05/form4.xml 0000905148-24-003224 4438
2024-11-18 4 xslF345X05/form4.xml 0000905148-24-003223 8121
2024-11-13 10-Q 10-Q 0000950170-24-125929 001-41551 241451145 34 7786065 1 1
2024-11-13 8-K 8-K 2.02,9.01 0000950170-24-125920 001-41551 241451110 34 351565 1 1
2024-10-21 4 xslF345X05/form4.xml 0000905148-24-002773 4428
2024-10-11 8-K 8-K 7.01,8.01,9.01 0000950170-24-114213 001-41551 241366430 34 206371 1 1
2024-10-03 4 xslF345X05/form4.xml 0000905148-24-002637 4428
2024-09-16 8-K 8-K 7.01,8.01,9.01 0001193125-24-219180 001-41551 241299285 34 6711153 1 1
2024-08-23 4 xslF345X05/form4.xml 0000905148-24-002335 7291
2024-08-16 4 xslF345X05/form4.xml 0000905148-24-002283 4419
2024-08-16 4 xslF345X05/form4.xml 0000905148-24-002282 4428
2024-08-16 4 xslF345X05/form4.xml 0000905148-24-002281 5479
2024-08-16 4 xslF345X05/form4.xml 0000905148-24-002280 4440
2024-08-16 4 xslF345X05/form4.xml 0000905148-24-002279 4444
2024-08-16 4 xslF345X05/form4.xml 0000905148-24-002278 4438
2024-08-16 4 xslF345X05/form4.xml 0000905148-24-002277 5489
2024-08-13 8-K 8-K 2.02,9.01 0000950170-24-095766 001-41551 241198834 34 329669 1 1
2024-08-13 10-Q 10-Q 0000950170-24-095760 001-41551 241198793 34 7508606 1 1
2024-07-19 4 FORM 4 0001140361-24-033600 4448
2024-07-10 SC 13G/A AMENDMENT NO. 2 TO SCHEDULE 13G 0001213900-24-060604 005-93824 241110900 34 92937
2024-07-10 SC 13G/A AMENDMENT NO. 1 TO SCHEDULE 13G 0001213900-24-060601 005-93824 241110894 34 123287
2024-06-24 4 xslF345X05/form4-06242024_090612.xml 0001415889-24-018035 13829
2024-06-24 4 xslF345X05/form4.xml 0000905148-24-001777 16161
2024-06-24 4 xslF345X05/form4.xml 0000905148-24-001776 5094
2024-06-24 4 xslF345X05/form4.xml 0000905148-24-001775 16847
2024-06-24 4 xslF345X05/form4.xml 0000905148-24-001774 5096
2024-06-21 8-K 8-K 5.07 0000950170-24-075760 001-41551 241057621 34 172595 1 1
2024-05-21 4 xslF345X05/form4.xml 0000905148-24-001566 6634
2024-05-16 4 xslF345X05/form4.xml 0000905148-24-001495 4418
2024-05-16 4 xslF345X05/form4.xml 0000905148-24-001493 4427
2024-05-16 4 xslF345X05/form4.xml 0000905148-24-001491 5478
2024-05-16 4 xslF345X05/form4.xml 0000905148-24-001489 4439
2024-05-16 4 xslF345X05/form4.xml 0000905148-24-001487 4443
2024-05-16 4 xslF345X05/form4.xml 0000905148-24-001485 4437
2024-05-16 4 xslF345X05/form4.xml 0000905148-24-001483 5488
2024-05-16 3 xslF345X02/form3.xml 0000905148-24-001481 18835
2024-05-14 8-K 8-K 2.02,9.01 0000950170-24-059097 001-41551 24941498 34 290441 1 1
2024-05-14 10-Q 10-Q 0000950170-24-059084 001-41551 24941467 34 6436748 1 1
2024-04-29 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2024-04-29 09:00:00 9999999995-24-001188 333-278761 24893781 33 1705
2024-04-26 ARS ARS 0000950170-24-048675 001-41551 24879029 34 16866847
2024-04-26 DEFA14A DEFA14A 0000950170-24-048673 001-41551 24879013 34 2547043
2024-04-26 DEF 14A DEF 14A 0000950170-24-048671 001-41551 24878978 34 3264222
2024-04-24 CORRESP filename1.htm 0001193125-24-110404 6269
2024-04-24 8-K 8-K 2.02,7.01,8.01,9.01 0000950170-24-047560 001-41551 24870490 34 23881818 1 1
2024-04-19 4 xslF345X05/form4.xml 0000905148-24-001186 4428
2024-04-19 UPLOAD filename1.pdf 0000000000-24-004299 333-278761 40330
2024-04-17 S-3 S-3 0001193125-24-099152 333-278761 24851612 33 319998
2024-04-15 4 xslF345X05/form4-04152024_040401.xml 0001415889-24-010809 13210
2024-04-15 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-24-008378 8657
2024-04-15 SC 13G/A SC 13G/A 0001193125-24-095564 005-93824 24843186 34 63916
2024-04-11 SC 13D/A SC 13D/A 0001104659-24-046306 005-93824 24838716 34 93947
2024-04-09 8-K 8-K 1.01,3.02,7.01,9.01 0000950170-24-042789 001-41551 24831097 34 1292164 1 1
2024-03-29 S-8 S-8 0001193125-24-081596 333-278365 24802222 33 77903
2024-03-28 8-K 8-K 2.02,9.01 0000950170-24-037627 001-41551 24793594 34 327494 1 1
2024-03-28 10-K 10-K 0000950170-24-037618 001-41551 24793537 34 94467748 1 1
2024-03-06 4 xslF345X05/form4.xml 0000905148-24-000904 5216
2024-03-06 3 xslF345X02/form3.xml 0000905148-24-000901 14295
2024-03-04 8-K 8-K 5.02,9.01 0001193125-24-056937 001-41551 24712918 34 177996 1 1
2024-02-16 4 xslF345X05/form4.xml 0000905148-24-000765 4426
2024-02-16 4 xslF345X05/form4.xml 0000905148-24-000764 5477
2024-02-16 4 xslF345X05/form4.xml 0000905148-24-000763 4438
2024-02-16 4 xslF345X05/form4.xml 0000905148-24-000762 4442
2024-02-16 4 xslF345X05/form4.xml 0000905148-24-000761 4436
2024-02-16 4 xslF345X05/form4.xml 0000905148-24-000760 5487
2024-02-14 SC 13G/A SC 13G/A 0001104659-24-023918 005-93824 24639948 34 136606
2024-02-14 SC 13G/A SC 13G/A 0001193125-24-036370 005-93824 24639367 34 64609
2024-02-14 SC 13G/A ACRIVON THERAPEUTICS, INC. 0000902664-24-001626 005-93824 24633314 34 52019
2024-02-13 SC 13G/A acrv_13ga.htm 0000908834-24-000055 005-93824 24625332 34 66488
2024-02-09 4 xslF345X05/form4.xml 0000905148-24-000533 5401
2024-02-09 3 xslF345X02/form3.xml 0000905148-24-000531 14342
2024-02-08 8-K 8-K 5.02,9.01 0001193125-24-027629 001-41551 24606960 34 178409 1 1
2024-01-19 4 xslF345X05/form4.xml 0000905148-24-000240 4427
2024-01-16 4 xslF345X05/form4.xml 0000905148-24-000183 5238
2024-01-12 3 xslF345X02/form3.xml 0000905148-24-000165 14290
2024-01-08 8-K 8-K 7.01,9.01 0001193125-24-003885 001-41551 24518335 34 6760172 1 1
2023-12-15 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2023-12-15 16:30:00 9999999995-23-003657 333-275854 231492128 33 1706
2023-12-12 CORRESP filename1.htm 0001193125-23-293526 7994
2023-12-08 8-K 8-K 1.01 0001193125-23-291705 001-41551 231475683 34 147175 1 1
2023-12-05 UPLOAD filename1.pdf 0000000000-23-013218 40246
2023-12-01 S-3 S-3 0001193125-23-287501 333-275854 231460058 33 1170789
2023-11-16 4 xslF345X05/form4.xml 0000905148-23-001477 4346
2023-11-16 4 xslF345X05/form4.xml 0000905148-23-001476 17516
2023-11-16 4 xslF345X05/form4.xml 0000905148-23-001475 4359
2023-11-16 4 xslF345X05/form4.xml 0000905148-23-001474 4359
2023-11-16 4 xslF345X05/form4.xml 0000905148-23-001473 4357
2023-11-16 4 xslF345X05/form4.xml 0000905148-23-001472 5408
2023-11-09 8-K 8-K 2.02,7.01,9.01 0001193125-23-274124 001-41551 231390316 34 19683457 1 1
2023-11-09 10-Q 10-Q 0000950170-23-061553 001-41551 231390149 34 9489691 1 1
2023-10-19 4 xslF345X05/form4.xml 0000905148-23-001156 4347
2023-09-28 4 xslF345X05/form4.xml 0000905148-23-001029 7041
2023-09-28 3 xslF345X02/form3.xml 0000905148-23-001028 18952
2023-09-05 8-K 8-K 7.01,9.01 0001193125-23-228639 001-41551 231236984 34 18757571 1 1
2023-08-23 4 xslF345X05/form4.xml 0000905148-23-000783 5699
2023-08-11 S-8 S-8 0001193125-23-209859 333-273908 231161645 33 80205
2023-08-11 8-K 8-K 2.02,9.01 0001193125-23-209745 001-41551 231161504 34 234091 1 1
2023-08-11 10-Q 10-Q 0000950170-23-041593 001-41551 231161493 34 9789976 1 1
2023-06-28 4 xslF345X04/form4.xml 0001140361-23-031959 5138
2023-06-28 3 xslF345X02/form3.xml 0001140361-23-031954 15421
2023-06-28 4 xslF345X04/ownership.xml 0001213900-23-052442 13967
2023-06-22 8-K 8-K 5.07 0000950170-23-029447 001-41551 231034067 34 233313 1 1
2023-06-20 4 xslF345X04/form4.xml 0001140361-23-030544 16966
2023-06-20 4 xslF345X04/ownership.xml 0001213900-23-050160 13998
2023-06-14 4 xslF345X04/ownership.xml 0001213900-23-049014 17635
2023-06-12 144 xsl144X01/primary_doc.xml 0001971857-23-000245 001-41551 231007516 33 4610
2023-06-06 4 xslF345X04/form4.xml 0001140361-23-028539 17126
2023-06-05 8-K 8-K 1.01,9.01 0001193125-23-160789 001-41551 23993555 34 310414 1 1
2023-06-01 4 xslF345X04/form4.xml 0001140361-23-027860 20060
2023-05-30 DEFR14A DEFR14A 0001193125-23-156608 001-41551 23976765 34 433948
2023-05-09 8-K 8-K 2.02,9.01 0001193125-23-138948 001-41551 23900084 34 255186 1 1
2023-05-09 10-Q 10-Q 0000950170-23-019157 001-41551 23900066 34 9157880 1 1
2023-05-01 ARS ARS 0000950170-23-016275 001-41551 23874153 34 3691709
2023-05-01 DEFA14A DEFA14A 0000950170-23-016272 001-41551 23874077 34 1104435
2023-05-01 DEF 14A DEF 14A 0000950170-23-016268 001-41551 23874029 34 3916150
2023-05-01 8-K 8-K 7.01,9.01 0001193125-23-129712 001-41551 23871896 34 12753215 1 1
2023-05-01 8-K 8-K 2.02 0001193125-23-128896 001-41551 23870365 34 147711 1 1
2023-04-25 8-K 8-K 7.01,9.01 0001193125-23-114750 001-41551 23843069 34 15186748 1 1
2023-03-30 SC 13D/A SC 13D/A 0001104659-23-039254 005-93824 23781616 34 91537
2023-03-29 S-8 S-8 0001193125-23-082963 333-270923 23771840 33 73804
2023-03-28 10-K 10-K 0000950170-23-010331 001-41551 23770204 34 111349450 1 1
2023-03-28 8-K 8-K 2.02,9.01 0001193125-23-081445 001-41551 23766257 34 237159 1 1
2023-03-13 8-K 8-K 2.02,7.01,9.01 0001193125-23-068545 001-41551 23725880 34 15088151 1 1
2023-03-03 8-K 8-K 8.01 0001193125-23-060173 001-41551 23705558 34 150125 1 1
2023-02-14 SC 13G/A 13ga1_acrivon.htm 0001175707-23-000086 005-93824 23627901 34 100556
2023-02-14 SC 13G/A SC 13G/A 0001193125-23-038734 005-93824 23627265 34 65405
2023-02-14 SC 13G ACRIVON THERAPEUTICS, INC. 0000902664-23-001677 005-93824 23623492 34 50222
2023-02-14 SC 13G/A SC 13G/A 0001104659-23-020729 005-93824 23622661 34 137887
2022-12-15 10-Q 10-Q 0000950170-22-026622 001-41551 221465455 34 10338901 1 1
2022-11-28 SC 13D SC 13D 0001104659-22-122435 005-93824 221425935 34 101284
2022-11-28 SC 13G SCHEDULE 13G 0001213900-22-075488 005-93824 221425281 34 92919
2022-11-25 SC 13G SC 13G 0001193125-22-292633 005-93824 221420415 34 57401
2022-11-21 4 xslF345X03/ownership.xml 0001213900-22-074313 21891
2022-11-21 4 OWNERSHIP DOCUMENT 0001104659-22-120780 21015
2022-11-21 SC 13G SC 13G 0001104659-22-120743 005-93824 221405722 34 133844
2022-11-21 4 4 0000950170-22-025513 7109
2022-11-18 3 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES 0001062993-22-022492 7743
2022-11-18 SC 13G SC 13G 0001193125-22-289031 005-93824 221402343 34 65243
2022-11-17 8-K 8-K 3.02,5.03,8.01,9.01 0001193125-22-287727 001-41551 221399089 34 221958
2022-11-17 S-8 S-8 0001193125-22-287229 333-268426 221396845 33 103740
2022-11-16 4 FORM 4 SUBMISSION 0001209191-22-057421 6131
2022-11-16 4 OWNERSHIP DOCUMENT 0001104659-22-119645 13824
2022-11-16 4 FORM 4 SUBMISSION 0001209191-22-057405 5481
2022-11-16 4 FORM 4 SUBMISSION 0001209191-22-057401 5439
2022-11-16 4 FORM 4 SUBMISSION 0001209191-22-057400 7616
2022-11-16 4 FORM 4 SUBMISSION 0001209191-22-057399 7617
2022-11-16 4 FORM 4 SUBMISSION 0001209191-22-057398 7612
2022-11-16 4 FORM 4 SUBMISSION 0001209191-22-057397 16450
2022-11-16 4 FORM 4 SUBMISSION 0001209191-22-057395 16662
2022-11-16 424B4 424B4 0001193125-22-286805 333-267911 221395560 33 8577523
2022-11-14 S-1MEF S-1MEF 0001193125-22-285005 333-268365 221389084 33 78759
2022-11-14 3/A xslF345X02/ownership.xml 0001213900-22-072518 45408
2022-11-14 FWP FWP 0001193125-22-284824 333-267911 221387864 34 64579
2022-11-09 SEC STAFF LETTER filename1.pdf 9999999997-22-004721 275386
2022-11-09 EFFECT xslEFFECTX01/primary_doc.xml S-1,,2022-11-09 17:00:00 9999999995-22-003246 333-267911 221374652 33 1657
2022-11-09 3 xslF345X02/ownership.xml 0001213900-22-070760 58660
2022-11-09 3 FORM 3 SUBMISSION 0000899243-22-035474 4767
2022-11-09 3 FORM 3 SUBMISSION 0001209191-22-056309 6545
2022-11-09 3 FORM 3 SUBMISSION 0001209191-22-056308 10010
2022-11-09 3 FORM 3 SUBMISSION 0001209191-22-056307 6574
2022-11-09 3 OWNERSHIP DOCUMENT 0001104659-22-116650 13474
2022-11-09 3 FORM 3 SUBMISSION 0001209191-22-056306 13151
2022-11-09 3 FORM 3 SUBMISSION 0001209191-22-056305 9255
2022-11-09 3 FORM 3 SUBMISSION 0001209191-22-056304 13156
2022-11-09 3 FORM 3 SUBMISSION 0001209191-22-056303 6545
2022-11-09 3 FORM 3 SUBMISSION 0001209191-22-056302 7971
2022-11-08 CERT 8A_Cert_ACRV.pdf 0001354457-22-000634 001-41551 221367946 34 217169
2022-11-08 S-1/A S-1/A 0001193125-22-279682 333-267911 221367230 33 8647799
2022-11-07 CORRESP filename1.htm 0001193125-22-279086 8415
2022-11-07 CORRESP filename1.htm 0001193125-22-279075 13695
2022-11-07 8-A12B 8-A12B 0001193125-22-279053 001-41551 221365368 34 13601
2022-11-03 S-1/A S-1/A 0001193125-22-276311 333-267911 221356016 33 9390224
2022-10-17 CORRESP filename1.htm 0001193125-22-263777 30398
2022-10-17 S-1 S-1 0000950123-22-010286 333-267911 221314188 33 10057529
2022-10-05 UPLOAD filename1.pdf 0000000000-22-010958 51138
2022-09-22 DRSLTR filename1.htm 0000950123-22-009914 79110
2022-09-22 DRS/A filename1.htm 0000950123-22-009913 377-06317 221260133 33 9219923
2022-09-14 SEC STAFF LETTER filename1.pdf 9999999997-22-004170 276254
2022-09-12 UPLOAD filename1.pdf 0000000000-22-009877 68495
2022-08-12 DRS filename1.htm 0000950123-22-008876 377-06317 221161110 33 8092327
2021-11-23 D xslFormDX01/primary_doc.xml 06b 0001781174-21-000002 021-422273 211438391 33 10806
2021-02-12 D xslFormDX01/primary_doc.xml 06b 0001781174-21-000001 021-389339 21625129 33 8933

Latest XBRL company facts

One latest value per concept from companyfacts (199 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 42.91M 2026-11-10 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
dei EntityPublicFloat Entity Public Float USD 20.40M 2025-06-30 2025 FY 10-K 2026-03-19 0001193125-26-115123
ffd NetFeeAmt NetFeeAmt USD 635.01 2026-11-13 S-3 2026-11-16 0001193125-26-463828
ffd TtlFeeAmt TtlFeeAmt USD 635.01 2026-11-13 S-3 2026-11-16 0001193125-26-463828
ffd TtlOfferingAmt TtlOfferingAmt USD 300.00M 2026-11-13 S-3 2026-11-16 0001193125-26-463828
ffd TtlOffsetAmt TtlOffsetAmt USD 0 2026-11-13 S-3 2026-11-16 0001193125-26-463828
ffd TtlPrevslyPdAmt TtlPrevslyPdAmt USD 0 2026-11-13 S-3 2026-11-16 0001193125-26-463828
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 616,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD -54,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap AccruedEmployeeBenefitsCurrent Accrued Employee Benefits, Current USD 4.27M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap AccruedLiabilitiesAndOtherLiabilities Accrued Liabilities and Other Liabilities USD 12.55M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap AccruedProfessionalFeesCurrent Accrued Professional Fees, Current USD 513,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 4.52M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -26,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 400.54M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 6.39M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap Assets Assets USD 85.75M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap AssetsCurrent Assets, Current USD 79.08M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 111,000 2025-12-31 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 26,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 30.24M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap AvailableForSaleDebtSecuritiesGrossUnrealizedLoss Debt Securities, Available-for-sale, Unrealized Loss USD 133,000 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-12-15 0000950170-22-026622
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 30.22M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrent Debt Securities, Available-for-sale, Current USD 91.44M 2023-12-31 2024 Q3 10-Q 2024-11-13 0000950170-24-125929
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 47.53M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 76.80M 2022-09-30 2022 Q3 10-Q 2022-12-15 0000950170-22-026622
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 47.73M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations USD 47.73M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD 6.03M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding shares 0 2026-03-31 2026 Q1 10-Q 2026-05-13 0001193125-26-221634
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 5.55M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 500.00M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 42.91M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 42.91M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap CommonStockValue Common Stock, Value, Issued USD 42,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -55.04M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD 122.52M 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-28 0000950170-24-037618
us-gaap ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion shares 11.14M 2021-12-31 2022 FY 10-K 2023-03-28 0000950170-23-010331
us-gaap DebtSecuritiesAvailableForSaleAllowanceForCreditLoss Debt Securities, Available-for-sale, Allowance for Credit Loss USD 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap DebtSecuritiesAvailableForSaleAmortizedCostCurrent Debt Securities, Available-for-sale, Amortized Cost, Current USD 91.53M 2023-12-31 2024 Q3 10-Q 2024-11-13 0000950170-24-125929
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer USD 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months USD 30.20M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap DebtSecuritiesAvailableForSaleUnrealizedLossPosition Debt Securities, Available-for-sale, Unrealized Loss Position USD 0 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap DeferredCosts Deferred Costs, Noncurrent USD 1.54M 2022-09-30 2022 Q3 10-Q 2022-12-15 0000950170-22-026622
us-gaap DeferredOfferingCosts Deferred Offering Costs USD 500,000 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 78.32M 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap DeferredTaxAssetsInProcessResearchAndDevelopment Deferred Tax Assets, in Process Research and Development USD 16.60M 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 1.10M 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 42.19M 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap DeferredTaxAssetsOther Deferred Tax Assets, Other USD 1.24M 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap DeferredTaxAssetsTaxCreditCarryforwards Deferred Tax Assets, Tax Credit Carryforwards USD 13.39M 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 77.22M 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap DeferredTaxLiabilities Deferred Tax Liabilities, Net USD 1.10M 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap DeferredTaxLiabilitiesPropertyPlantAndEquipment Deferred Tax Liabilities, Property, Plant and Equipment USD 408,000 2024-12-31 2024 FY 10-K 2025-03-27 0000950170-25-046056
us-gaap DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount USD 300,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap Depreciation Depreciation USD 1.20M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -1.33 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -1.33 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.209 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent pure 0.06 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-27 0000950170-25-046056
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.01 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Amount USD 2.05M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent pure -0.026 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent pure -0.035 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap ForeignCurrencyTransactionGainLossBeforeTax Foreign Currency Transaction Gain (Loss), before Tax USD 200,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 13.53M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic Income (Loss) from Continuing Operations before Income Taxes, Domestic USD -78.01M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -77.83M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign Income (Loss) from Continuing Operations before Income Taxes, Foreign USD 189,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 16.24M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -16.34M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 25,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 769,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD -16,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap IncomeTaxReconciliationTaxCreditsResearch Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount USD 2.69M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD -1.66M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap IncreaseDecreaseInOperatingLeaseLiability IncreaseDecreaseInOperatingLeaseLiability USD -905,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap IncreaseDecreaseInOtherNoncurrentAssets Increase (Decrease) in Other Noncurrent Assets USD -234,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD -534,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap InterestIncomeExpenseNonoperatingNet Interest Income (Expense), Nonoperating, Net USD 2.60M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap InvestmentIncomeInterest Investment Income, Interest USD 7.00M 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-037618
us-gaap LeaseCost Lease, Cost USD 1.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap LeaseholdImprovementsGross Leasehold Improvements, Gross USD 0 2022-12-31 2023 FY 10-K 2024-03-28 0000950170-24-037618
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 1.91M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Lessee, Operating Lease, Liability, to be Paid, after Year Five USD 404,000 2022-12-31 2022 FY 10-K 2023-03-28 0000950170-23-010331
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Lessee, Operating Lease, Liability, to be Paid, Year One USD 1.21M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFive Lessee, Operating Lease, Liability, to be Paid, Year Five USD 404,000 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-037618
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearFour Lessee, Operating Lease, Liability, to be Paid, Year Four USD 404,000 2024-12-31 2024 FY 10-K 2025-03-27 0000950170-25-046056
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearThree Lessee, Operating Lease, Liability, to be Paid, Year Three USD 404,000 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Lessee, Operating Lease, Liability, to be Paid, Year Two USD 404,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 300,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 109,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap Liabilities Liabilities USD 14.97M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 85.75M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap LiabilitiesCurrent Liabilities, Current USD 14.28M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap LongTermInvestments Long-term Investments USD 5.09M 2024-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD 7.24M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD 46.57M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -47.78M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -54.90M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap NonoperatingIncomeExpense Nonoperating Income (Expense) USD 2.19M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap OperatingExpenses Operating Expenses USD 57.09M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -57.09M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap OperatingLeaseCost Operating Lease, Cost USD 1.29M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 1.80M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 1.11M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 693,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap OperatingLeasePayments Operating Lease, Payments USD 1.30M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 1.69M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.082 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 245,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap OtherAssetImpairmentCharges Other Asset Impairment Charges USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 945,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax USD -137,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap OtherComprehensiveIncomeLossTax Other Comprehensive Income (Loss), Tax USD -27.00M 2023-01-01 2023-06-30 2023 Q2 10-Q 2023-08-11 0000950170-23-041593
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD -412,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap PaymentsOfStockIssuanceCosts Payments of Stock Issuance Costs USD 4,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap PaymentsRelatedToTaxWithholdingForShareBasedCompensation Payment, Tax Withholding, Share-based Payment Arrangement USD 67,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap PaymentsToAcquireAvailableForSaleSecuritiesDebt Payments to Acquire Debt Securities, Available-for-sale USD 26.82M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 101,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0.001 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 10.00M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 1.33M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 99.81M 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-28 0000950170-24-037618
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 7.30M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ProceedsFromIssuanceOfPrivatePlacement Proceeds from Issuance of Private Placement USD 70.00M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock Proceeds from Issuance of Redeemable Convertible Preferred Stock USD 12.47M 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-28 0000950170-23-010331
us-gaap ProceedsFromIssuanceOfWarrants Proceeds from Issuance of Warrants USD 60.00M 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities Proceeds from Sale and Maturity of Debt Securities, Available-for-sale USD 73.50M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 8,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -54.90M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 8.35M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 3.83M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 43.56M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap RestrictedCash Restricted Cash USD 196,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap RestrictedCashNoncurrent Restricted Cash, Noncurrent USD 196,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap RestrictedStockValueSharesIssuedNetOfTaxWithholdings Restricted Stock, Value, Shares Issued Net of Tax Withholdings USD -34,000 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -329.78M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 56,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap SegmentReportingOtherItemAmount SegmentReportingOtherItemAmount USD -2.19M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 6.39M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number shares 935,963 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum pure 1.016 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum pure 1.005 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate pure 0.029 2022-07-01 2022-09-30 2023 Q3 10-Q 2023-11-09 0000950170-23-061553
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum pure 0.049 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum pure 0.036 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 630,000 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 100,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period shares 342,077 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period shares 344,368 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-13 0001193125-26-221634
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price USD/shares 4.33 2026-01-01 2026-03-31 2026 Q1 10-Q 2026-05-13 0001193125-26-221634
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period shares 651,411 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 2.91M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 4.07 2022-07-01 2022-09-30 2023 Q3 10-Q 2023-11-09 0000950170-23-061553
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 1.94M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 8.08M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 4.46 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number shares 3.84M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price USD/shares 6.17 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 1.94M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 8.08M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price USD/shares 4.46 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 1.04 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price USD/shares 8.94 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price USD/shares 3.97 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 1.57 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ShortTermInvestments Short-term Investments USD 30.22M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap ShortTermLeaseCost Short-term Lease, Cost USD 131,000 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-28 0000950170-23-010331
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 70.77M 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.406 2022-11-17 2023 FY 10-K 2024-03-28 0000950170-24-037618
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 8,110 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 349,000 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-28 0000950170-23-010331
us-gaap StockIssuedDuringPeriodValueShareBasedCompensation Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture USD 2.00M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 8,000 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap SubleaseIncome Sublease Income USD 134,000 2023-01-01 2023-12-31 2024 FY 10-K 2025-03-27 0000950170-25-046056
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 122.52M 2021-12-31 2022 FY 10-K 2023-03-28 0000950170-23-010331
us-gaap TemporaryEquityLiquidationPreference Temporary Equity, Liquidation Preference USD 122.85M 2021-12-31 2022 FY 10-K 2023-03-28 0000950170-23-010331
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 27.47M 2021-12-31 2022 FY 10-K 2023-03-28 0000950170-23-010331
us-gaap TemporaryEquitySharesIssued Temporary Equity, Shares Issued shares 27.47M 2021-12-31 2022 FY 10-K 2023-03-28 0000950170-23-010331
us-gaap TemporaryEquitySharesOutstanding Temporary Equity, Shares Outstanding shares 27.47M 2021-12-31 2022 FY 10-K 2023-03-28 0000950170-23-010331
us-gaap UnrealizedGainLossOnInvestments Unrealized Gain (Loss) on Investments USD -100,000 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-28 0000950170-24-037618
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 0 2024-12-31 2024 FY 10-K 2025-03-27 0000950170-25-046056
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount USD 20.60M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap VariableLeaseCost Variable Lease, Cost USD 608,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-19 0001193125-26-115123
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 41.16M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 41.16M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-16 0001193125-26-463419

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →